Status:
ACTIVE_NOT_RECRUITING
Different Immunochemotherapies in Small B-cell Non-Hodgkin Lymphoma (iNHL)
Lead Sponsor:
Fudan University
Conditions:
Lymphoma, Non-Hodgkin
Eligibility:
All Genders
18+ years
Brief Summary
Describe the application status of different immunochemotherapies in small B-cell non-Hodgkin lymphoma (iNHL), observe the therapeutic efficacy and safety of the treatment modalities.
Detailed Description
Evaluated the efficacy and safety of different immunochemotherapies in small B-cell non-Hodgkin lymphoma (iNHL)
Eligibility Criteria
Inclusion
- Age ≥ 18 years old
- Initial or first recurrent iNHL confirmed by histopathology, including FL (1-3a), MZL, MCL;
- Sign an informed consent form;
- Researchers evaluate patients who can benefit from receiving immunochemotherapy.
Exclusion
- There are contraindications to any medication in the treatment plan;
- Pregnant or lactating women or male and female participants of childbearing age did not take contraceptive measures during the trial period and within 30 days after the last medication;
- Researchers believe that patients who are not suitable for enrollment.
Key Trial Info
Start Date :
January 10 2023
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
January 10 2026
Estimated Enrollment :
220 Patients enrolled
Trial Details
Trial ID
NCT06170216
Start Date
January 10 2023
End Date
January 10 2026
Last Update
February 23 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Fudan University Shanghai Cancer Center
Shanghai, Shanghai Municipality, China, 200032